Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
JPMorgan Chase & Co. and its affiliates have reduced their voting power in Mesoblast Limited, a biotechnology company, from 8.34% to 7.16%. This change in substantial holding reflects various transactions, including securities on loan and rehypothecation under a prime brokerage agreement, indicating a shift in the investment strategy by JPMorgan, which may impact Mesoblast’s shareholder dynamics.
More about Mesoblast Limited
YTD Price Performance: -0.91%
Average Trading Volume: 101,786
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.1B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.
